Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Immunogenicity and Safety Study
NCT05574985Completed
- Sponsor
- Zhifei Biological
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of recombinant omicron-delta COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Zhifei Biological. Primary endpoint: Geometric Mean Titer (GMT) of neutralizing antibody in serum against SARS-CoV-2 Delta, BA.2, and BA.5 at 14 days. Started Aug 2022; status: completed.
02
Drugs
recombinant omicron-delta COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05574985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574985.